DW
About
David de Weese joined Paul Capital in 1995 and leads global secondary transaction sourcing activities for the firm. Following fourteen years of management experience in Europe, Mr. de Weese served as President and CEO of biotechnology company, SigA Pharmaceuticals; California-based pharmaceutical company Cygnus Therapeutic Systems; and a Silicon Valley software company. Mr. de Weese received a B.A. from Stanford University, an M.B.A. from the Harvard Business School and attended law school at Stanford University.
Position in the VCSift Database
- • 16 investors at Paul Capital are tracked.
- • 2,531 investors hold the Partner role in VCSift. David de Weese is one of them.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
Contact Information
linkedin.com/in/••••••••
Find more investors like David de
Search Investors